Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma

This study is ongoing, but not recruiting participants.

First Received: October 9, 2007 No Changes Posted

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00541411

Purpose

Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide combination chemotherapy in Ewing's Sarcoma

Condition	Intervention
Ewing's Sarcoma	Drug: Vincristine, Actinomycin-D, Ifosfamide

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Resource links provided by NLM:

MedlinePlus related topics: Soft Tissue Sarcoma

Drug Information available for: Dactinomycin Vincristine Vincristine sulfate Ifosfamide

U.S. FDA Resources

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Patients with Ewing's Sarcoms

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00541411

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:

Muhammad Memon, MD

King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

More Information

No publications provided

Study ID Numbers:	RAC#2031-065
Study First Received:	October 9, 2007
Last Updated:	October 9, 2007
ClinicalTrials.gov Identifier:	NCT00541411 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Anti-Infective Agents
Vincristine
Osteosarcoma
Antimitotic Agents
Ewing's Sarcoma
Doxorubicin
Anti-Bacterial Agents
Neoplasms, Connective and Soft Tissue
Sarcoma, Ewing's
Malignant Mesenchymal Tumor
Soft Tissue Sarcomas

Ifosfamide
Dactinomycin
Mechlorethamine
Tubulin Modulators
Sarcoma
Osteogenic Sarcoma
Antineoplastic Agents, Alkylating
Ewing's Family of Tumors
Antineoplastic Agents, Phytogenic
Alkylating Agents
Isophosphamide mustard

Additional relevant MeSH terms:

Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antibiotics, Antineoplastic
Neoplasms, Connective and Soft Tissue
Anti-Bacterial Agents
Sarcoma, Ewing's
Dactinomycin
Therapeutic Uses
Alkylating Agents
Nucleic Acid Synthesis Inhibitors
Neoplasms by Histologic Type
Mitosis Modulators
Vincristine

Osteosarcoma
Enzyme Inhibitors
Antimitotic Agents
Pharmacologic Actions
Protein Synthesis Inhibitors
Ifosfamide
Neoplasms
Neoplasms, Bone Tissue
Tubulin Modulators
Sarcoma
Neoplasms, Connective Tissue
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Isophosphamide mustard

ClinicalTrials.gov processed this record on August 28, 2009